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ABSTRACT 
 
 
 
 
BACKGROUND 
 
Chronic obstructive pulmonary disease (COPD) and lung cancer are two catastrophic diseases, 
representing leading causes of morbidity and mortality worldwide. 
Although the treatment has greatly improved both diseases continue to show increasing 
frequency and above all an unpredictable progression. 
Several studies have firmly established a strict connection between COPD and lung cancer 
highlighting also the importance of the inflammatory response as a risk factor for both diseases. 
The inflammatory paradigm is undoubtedly one of the most fascinating theories to connect 
COPD and lung cancer and it has acquired new impetus by the recent discoveries in the COPD 
pathogenesis. Emerging evidence in this context has emphasized the role of adaptive immune 
responses, possibly with an autoimmune component due to the recognition of pulmonary self-
antigens modified by cigarette smoking and to the failure of mechanisms regulating 
immunological tolerance. In this context, COPD-associated cancers might have specific 
pathogenetic and morphological features, differently from tumours arising in non-COPD 
patients, due to the synergic effect of cigarette smoke and chronic inflammation. 
 
AIM OF THE RESEARCH 
 
This research project focuses on the study of lung cancer in patients with COPD compared to 
smokers without COPD and never smoker patients in order to identify eventual distinct clinical, 
morphological and molecular phenotypes.  
 
MATERIALS AND METHODS 
 
From 2010 to 2012, we prospectively enrolled patients with peripheral non small lung cancer 
submitted to anatomical lung resection (lobectomy, bilobectomy or pneumonectomy) associated 
with systematic lymphadenectomy. Patients with central airway cancer, secondary lung tumours 
or previously submitted to inductive treatment were excluded from the study. 
According to respiratory functional tests and smoking history patients were then divided in 3 
groups: COPD patients, smokers without COPD and never-smoker subjects with normal lung 
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function (FEV1/FVC ratio >70%). Each patient underwent a full clinical and instrumental 
assessment. 
Morphological studies included detailed analysis of growth pattern (according to the latest 
revision of adenocarcinoma classification), cell proliferation (Ki67/MIB1 expression), 
parameters of intra-and peri-tumoral remodelling (inflammation, fibrosis and necrosis) and 
tumoural detection of interleukin-17 (IL-17) cytokine. Genetic analysis of EGFR and KRAS 
mutations was also performed in all cases.  
 
RESULTS 
 
In the study period, 66 patients who met the inclusion/exclusion criteria were initially 
enrolled:16 COPD, 32 smokers without COPD and 18 never smokers. 
As the selection criteria affected the predominant histologic profile with a clear predominance of 
the adenocarcinoma histotype (63% in COPD patients, 71% in smokers and 56% in never-
smokers), we performed our investigations only in patients with this histology to obtain results 
not affected by different histotypes. Therefore the study group was composed of 43 patients (10 
COPD, 23 smokers and 10 never-smokers), whose main demographic and functional parameters 
were comparable except for male/female ratio, reversed in never-smokers, and for lung function, 
reduced in COPD patients, as expected. 
Given the specific aim the comparison of different clinical, morphological and molecular data 
was mainly performed within the category of smoking patients (COPD patients and smokers 
without COPD), while never smokers represented control group. 
From a clinical point of view the most important differences concern the number of peripheral 
blood basophils and standard uptake value of positron emission tomography–computed 
tomography (SUV of PET-CT). COPD patients showed a significant higher number of basophils 
and lower SUV of PET-CT than smokers without COPD. 
Concerning the histological evaluation adenocarcinoma of COPD patients showed a more 
frequent lepid  pattern, less evident solid aspect and lower MIB1/Ki67 index than 
adenocarcinoma of smokers without COPD. A significant more extensive necrosis was found in 
adenocarcinoma of COPD and smokers without COPD compared to never-smokers. Finally 
although not statistically significant a stronger IL17 tissue expression was observed in COPD 
cases compared to smokers without COPD. 
As regards molecular data the most interesting finding was a trend of less frequency of KRAS 
mutation in adenocarcinoma of COPD patients. 
 
 
  3 
CONCLUSIONS 
 
Adenocarcinoma in COPD patients presents clinical, molecular and morphological features of 
lower aggressiveness (higher number of basophils, low SUV of PET-CT, increased lepidic 
component, reduced solid pattern, lower cell proliferation and less frequent K-RAS mutation) 
compared to that of smokers without COPD.  
Alternative mechanisms of carcinogenesis may be involved in the development/progression of 
lung cancer in COPD patients. Given the importance of inflammation in the pathogenesis of the 
disease other mechanisms, such as IL-17 pathway, mainly driving inflammatory mediated 
carcinogenesis might be crucial. 
Additional knowledge of these mechanisms would be of considerable help in the fight against 
lung cancer especially concerning therapeutic perspectives, providing a rational basis for the 
development of targeted and more effective treatments.  
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RIASSUNTO 
 
 
INTRODUZIONE 
 
La BPCO e il tumore polmonare sono due malattie catastrofiche e rappresentano alcune tra le 
principali cause di morbilità e mortalità in tutto il mondo. 
Sebbene il trattamento di queste patologie è notevolmente migliorato negli ultimi anni, esse 
continuano a presentare una crescente incidenza e soprattutto un andamento clinico non 
prevedibile a priori.  
Lo stesso termine "tumore polmonare non a piccole cellule (NSCLC)" comprende un gruppo di 
malattie neoplastiche con caratteristiche cliniche e molecolari estremamente eterogenee. 
Diversi studi hanno ormai fermamente stabilito la stretta connessione tra la BPCO e il cancro del 
polmone evidenziando anche l'importanza della risposta infiammatoria agli stimoli nocivi, in 
particolare il fumo di sigaretta, come fattore di rischio fondamentale per entrambe le malattie. La 
teoria infiammatoria è senza dubbio uno dei paradigmi più affascinanti per collegare la BPCO e 
il tumore polmonare e ha acquisito un nuovo impulso dalle più recenti scoperte nella patogenesi 
della BPCO. 
Infatti, sono emerse in questo campo evidenze importanti che hanno sottolineato il ruolo 
fondamentale di risposte immunitarie adattative, anche con una componente autoimmune dovuta 
sia al riconoscimento di auto-antigeni polmonari modificati dal fumo di sigaretta sia al fallimento 
dei meccanismi che regolano la tolleranza immunologica. In questo contesto, le neoplasie a 
insorgenza in pazienti con BPCO, per effetto sinergico del fumo e di una specifica 
infiammazione cronica, potrebbero possedere specifiche caratteristiche patogenetiche e 
morfologiche, differenti da tumori di altre popolazioni non affette da BPCO.  
 
SCOPO DELLA RICERCA 
 
Questo progetto di ricerca si concentra sullo studio del cancro del polmone nei pazienti con 
BPCO comparandolo a due gruppi di controllo, composti da fumatori sani e pazienti non 
fumatori, al fine di individuare distinti fenotipi neoplastici dal punto di vista bioumorale, 
morfologico e molecolare. 
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MATERIALI E METODI 
 
Dal 2010 al 2012, sono stati arruolati nello studio pazienti con NSCLC  in sede periferica 
sottoposti a resezione polmonare anatomica (lobectomia, bilobectomia o pneumonectomia) 
associata a linfadenectomia sistematica. I pazienti con neoplasia a carico delle vie aeree centrali, 
con tumore polmonare secondario o precedentemente sottoposti a trattamento chemio-
radioterapico sono stati esclusi dal progetto. Ogni paziente è stato sottoposto ad una completa 
valutazione clinica e strumentale, che ha compreso i test di funzionalità polmonare polmonari (i 
criteri GOLD sono stati utilizzati per identificare i pazienti con BPCO), radiografia del 
torace/TAC torace/18FDG PET-TC analisi del sangue. 
I pazienti sono stati poi divisi in 3 gruppi in base alle prove funzionali respiratorie e alla storia di 
fumo: pazienti con BPCO, soggetti fumatori e pazienti non fumatori con funzione polmonare 
normale (rapporto FEV1/FVC> 70%). 
Lo studio istologico della neoplasia è stato caratterizzato da: stadiazione pTNM, analisi 
morfometrica del pattern di crescita (secondo l'ultima revisione della classificazione del cancro 
del polmone), proliferazione cellulare (mediante valutazione dell’espressione di Ki67/MIB1), i 
parametri di rimodellamento intra-e peri-tumorale (infiammazione, fibrosi, necrosi) e la 
caratterizzazione del pattern citochinico di IL-17 a livello peri-e intra-tumorale.   
Infine è stata eseguita l'analisi genetica delle mutazioni dei geni EGFR e KRAS. 
 
RISULTATI 
 
Nel periodo di studio sono stati inizialmente arruolati 66 pazienti che rispettavano i criteri di 
inclusione/esclusione, di cui 16 BPCO, 32 fumatori senza BPCO e 18 non fumatori. Poiché i 
criteri di selezione hanno profondamente condizionato il profilo istologico predominante, con 
una netta prevalenza dell’istotipo adenocarcinoma (63% nella BPCO, 71% nei fumatori e 56% 
nei non fumatori), abbiamo deciso di condurre la valutazione neoplastica funzionale, 
morfologica, molecolare solo nell’ istologia prevalente. 
Pertanto, il gruppo di studio è risultato composto da 43 pazienti (10 BPCO, 23 fumatori, 10  non 
fumatori), che presentavano comparabili dati demografici e funzionali ad eccezione del rapporto 
maschio/ femmina, invertito nei non fumatori, per la funzione polmonare, ridotta nei pazienti con 
BPCO. Dato l'obiettivo specifico, il confronto dei differenti dati clinici, morfologici e molecolari 
è stato svolto prevalentemente all'interno della categoria dei soggetti fumatori (pazienti affetti da 
BPCO e fumatori senza BPCO), mentre i pazienti con storia negativa di fumo hanno 
rappresentato il gruppo di controllo. 
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Da un punto di vista clinico, le più rimarcabili differenze sono emerse a livello del numero di 
basofili nel sangue periferico e del valore di standard uptake value (SUV) all’indagine PET-TC. 
Infatti i pazienti con BPCO hanno mostrato un numero significativamente superiore di basofili e 
un SUV inferiore rispetto ai soggetti fumatori senza BPCO. 
Per quanto riguarda la valutazione istologica, gli adenocarcinomi nei pazienti con BPCO 
hanno presentato un aumento del pattern lepidico, con riduzione della componente solida e una 
più bassa espressione del Ki67/MIB1 rispetto ai tumori dello stesso istotipo insorti in soggetti 
fumatori senza BPCO. Si è evidenziata una maggiore rappresentazione della componente 
necrotica negli adenocarcinomi dei pazienti fumatori, con o senza BPCO, rispetto al gruppo dei 
non fumatori. Infine un forte ma non significativo aumento di IL-17 è stato osservata nei casi con 
BPCO rispetto ai fumatori. 
L’analisi molecolare ha permesso di osservare, come dato più rilevante, un trend di ridotta 
frequenza di mutazione di KRAS negli adenocarcinomi dei pazienti con BPCO rispetto alle 
neoplasie del gruppo dei fumatori.  
 
CONCLUSIONI 
 
Gli adenocarcinomi correlati alla BPCO sono emersi presentare caratteristiche cliniche, 
morfologiche e molecolari di minore aggressività (aumento del numero di basofili, ridotto 
SUVmax alla PET-TC, aumento della componente lepidica, ridotti pattern solido e proliferazione 
cellulare e meno frequente mutazione di K-RAS) rispetto alle neoplasie insorte in pazienti 
fumatori senza BPCO. Vie alternative di carcinogenesi potrebbero essere coinvolte nello 
sviluppo/progressione del tumore polmonare dei pazienti con BPCO. Data l'importanza 
dell'infiammazione nella patogenesi di questa malattia polmonare, altri meccanismi, quale il 
pathway di IL-17, potrebbero essere cruciali per lo sviluppo cancerogenetico principalmente 
mediato dall’infiammazione. La conoscenza di questi meccanismi potrebbe essere di notevole 
aiuto nella lotta contro il tumore polmonare soprattutto per quanto riguarda nuove prospettive 
terapeutiche, fornendo le basi per sviluppare trattamenti mirati e con maggiore efficacia. 
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BACKGROUND 
 
1.1. DEFINITION OF COPD 
 
Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disorder of the lung, 
characterized by airflow limitation (bronchial obstruction),that is not fully reversible [1]. 
The airflow limitation is usually progressive and is associated with an abnormal inflammatory 
response of the lung to noxious particles or gases, primarily from cigarette smoking.  
In the past COPD was known with different names. Bonet described a condition of “voluminous 
lungs” in 1679. In 1769, Giovanni Morgagni reported 19 cases where the lungs were “turgid” 
particularly from air. The first description and illustration of the enlarged airspaces in 
emphysema was provided by Ruysh in 1721. Matthew Baillie illustrated an emphysematous lung 
in 1789 and described the destructive character of the condition. In 1814 Badham used the word 
“catarrh” to describe the cough and mucus hypersecretion of chronic bronchitis that was first 
reported as a disabling disorder. He recognised that chronic bronchitis was a disabling disorder. 
René Laennec, the physician who invented the stethoscope, used the term “emphysema (1837) to 
describe lungs that did not collapse as usual because they were full of air and the airways were 
filled with mucus. In 1842, John Hutchinson invented the spirometer, which allowed the 
measurement of vital capacity of the lungs. However, his spirometer could only measure volume, 
not airflow. Tiffeneau in 1947, and Gaensler in 1950 and 1951, described the principles of 
measuring airflow [2]. 
The terms chronic bronchitis and emphysema were formally defined at the CIBA guest 
symposium of physicians in 1959. The term COPD was first used by William Briscoe in 1965 
and has gradually overtaken other terms to become now the preferred name for this disease [3]. 
In 1977 Fletcher and Peto described COPD as an obstructive and hypersecretory chronic disorder 
of the airways, strictly related to cigarette smoke [4]. 
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The 1980 and 90s saw a surge in the use of medication to manage the symptoms of COPD and 
restore pulmonary function. A major push in COPD education meant that smoking cessation and 
clean air awareness became prime focuses of self-care treatment. 
Today it is known that a healthy lifestyle can help people with COPD to manage and improve 
their symptoms. Healthcare professionals stress the importance of diet, nutrition, and physical 
exercise as part of a COPD rehabilitation program. Over the years, physicians have done much to 
help understand the causes, diagnosis, and progression of COPD.  
 
1.2 EPIDEMIOLOGY  
 
COPD is a major cause of morbidity and mortality worldwide, resulting in a significant 
economic and social costs and growing [1].  
It affects about 10% of the general population but the prevalence in heavy smokers may reach 
50%.  
The epidemiology varies considerably between countries and between population groups within 
the same nation and this difference may be related both to different exposure and individual 
susceptibility to risk factors and different methods and criteria for diagnostic characterization. 
The BOLD Study (Burden of Obstructive Lung Disease) [5], a prevalence study conducted in 
2007 on 9425 subjects in 12 different locations of the world, reported the following data: 
 
- Higher prevalence in males. 
 
-  Prevalence of disease progressively increase with age in both males and females. 
 
- Increased prevalence in parallel with the increase in the number of pack-years (number 
of cigarettes per day multiplied by years of smoking divided by 20). 
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- Substantial prevalence of COPD even in non-smokers: 11.3%. 
 
Most of the epidemiological data collected in Western countries shows that the diagnosis of 
COPD is found in less than 6% of the population, but it is reasonable to assume that the disease 
still remains under-diagnosed. 
On the one hand, the slow evolution of the natural history and lack of specificity of symptoms, 
especially in the early stages, are the cause of the delay with which patients come to medical 
attention. Secondly the population at risk is large, with absence of valid screening programs 
[6,7]. 
Since the disease was responsible for 4% of the total deaths, the WHO in 2001 placed this 
disease in fifth place among the leading causes of death in industrialized countries and in sixth 
place in the developing countries. It is expected that the prevalence and impact of the disease 
will increase in the coming decades, in parallel with the most exposure to recognized risk factors 
and aging population. By 2020, according to the BOLD Study, it is estimated that COPD will 
become the third leading cause of death in industrialized countries. 
 
1.3  CLINICAL ASPECTS 
 
1.3.1 LUNG SYMPTOMS  
In the lungs, COPD is mainly characterized by the presence of progressive stress dyspnea that 
can evolve to respiratory failure associated with chronic bronchitis. 
The obstruction of the small airways, responsible for the loss of lung function, has a slow and 
progressive development and typically occurs late, whereas the contribution of this part of the 
bronchial tree to expiratory flow is 10-15% of the total resistance [8]. Obstruction of the small 
airways and increased lung compliance determine an increase of exhalation duration,  
appearance of hyperinflation and increase in the residual volume. In addition to increase the 
functional dead space, hyperinflation causes a flattening of the diaphragm, thereby affecting its 
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contractile efficiency, and reduces the movements of the chest wall. This condition is clinically 
manifested with stress dyspnea and limitation of exercise tolerance [9]. 
The effort made by patients suffering from emphysema during exhalation, causes a pink colour 
in their faces, hence the term commonly used to refer to them, “Pink Puffers” [10]. With the 
progression of the disease, respiratory effort increases in association with expansion of the 
residual volume and an increase in the muscular work required for each breath. The result is a 
reduction in pulmonary and alveolar ventilation responsible for blood gas alterations such as 
chronic hypoxemia (PaO2 <55 mmHg) and hypercapnia (PaCO2> 45 mmHg) with a final result 
of pulmonary acidosis more or less offset by the retention of bicarbonate in the kidney [11]. 
 
Chronic bronchitis 
Clinical condition characterized by the presence of cough and sputum production for at least 
three months a year for two consecutive years. These symptoms may occur in the natural history 
of COPD at different times and with varying severity. Hypersecretion of mucus in the proximal 
airways, responsible for chronic bronchitis, however, does not correlate with the decline in lung 
function (FEV) in patients with COPD [12]. 
Patients with advanced COPD that have primarily chronic bronchitis rather than emphysema 
were commonly referred to as “blue bloaters” due to the bluish colour of the skin and lips 
(cyanosis) [9]. 
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TABLE 1.1 Clinical features of the principal COPD patterns, from Travis WD et al., atlas of nontumour 
pathology “Non-neoplastic disorders of the lower respiratory tract” (8). 
 
 
Pulmonary Hypertension 
The inefficient alveolar ventilation is associated with a reduction of vascular bed in the 
parenchyma which is on the base of hypoxic vasoconstriction. Even the destruction of alveolar 
septa in emphysema contributes to reduce the extension of the pulmonary capillary. An 
endothelial dysfunction is also present in pulmonary vessels, which correlates with the airways 
inflammation. The structural changes in the pulmonary arterioles occur progressively such as 
hypertrophy of the intima and in the second place of the tunica muscularis, and determine the 
persistent increase in resistance in the pulmonary microcirculation [13].  
These alterations lead to the development of pulmonary hypertension, which may appear in the 
advanced stages of COPD (FEV <25% predicted), and it is responsible for right ventricular 
hypertrophy and, ultimately, for cor pulmonaris. 
 
Exacerbations  
Exacerbations have a significant impact on morbidity, disease progression, disability and socio-
medical costs [14]. Bacterial or viral infections, often overlapping with other factors such as 
environmental pollutants are the principal cause of exacerbation. From a clinical point of view, 
exacerbations may lead to an increased cough, change in sputum characteristics, that becomes 
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more abundant and/or purulent, appearance of wheezing / whistling expiratory and worsening of 
dyspnea.  
During the course of the disease, the frequency and severity of exacerbations tends to increase, 
resulting in accelerated decline in lung function. 
 
1.3.2 COMORBIDITY AND SYSTEMIC INVOLVEMENT 
 
Comorbidities contribute to the overall severity in individual patients (Global Initiative for 
Chronic Obstructive Lung Disease, Revision 2011) [1]. Moreover, COPD also produces 
significant systemic consequences mainly due to the development of the systemic inflammation. 
Cardiovascular disease  
These are mainly acute cardiovascular events due to atherosclerosis: endothelial dysfunction, 
that occurs in the pulmonary vessels, becomes progressively a systemic condition, along with the 
spread of the inflammatory reaction. CRP (C-reactive protein) is a key marker of systemic 
inflammatory response and the serum level correlates with the risk of acute cardiovascular events 
(CAD), such as myocardial infarction, unstable angina, and others. In COPD, CRP levels 
correlate with the severity  of bronchial obstruction (ie, with the decline of FEV) and the risk of 
cardiac and pulmonary complications [15,16].  
Metabolic syndrome  
It is a complex disorder and an emerging clinical challenge,  recognised clinically by the findings 
of abdominal obesity, elevated triglycerides, atherogenic dyslipidaemia, elevated blood pressure, 
high blood glucose and/or insulin resistance, for which the relative risk is increased (RR = 1.8) 
especially in women [17]. Patients with COPD often have one or more component of the 
metabolic syndrome and osteoporosis (70% of patients) which are, at least in part, independent 
from treatment with steroids and/or the decreased physical activity.   
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COPD patients have an increased risk of fractures, especially at vertebral level, and it has a 
direct effect on lung function with reduced vital capacity (estimated a loss of 7% for each 
vertebral fracture) [18]. 
 
FIGURE 1.1 The central role of inflammation in comorbidity is associated with COPD. Inflammation appears to 
play a central role in the pathogenesis of COPD and other conditions that are increasingly being recognised as 
systemic inflammatory diseases. As part of the chronic inflammatory process, tumour necrosis factor (TNF)-a 
receptor polymorphisms are associated with increased severity of disease, possibly due to enhanced TNF-a 
effects. Also, C-reactive protein (CRP) levels can be increased directly by TNF-a and other cytokines. Elevated 
CRP and fibrinogen may be crucial in the pathogenesis of cardiovascular disease. Reactive oxygen species 
released as a result of COPD may enhance the likelihood of a patient developing cardiovascular disease, diabetes 
and osteoporosis. IL: interleukin;?: unknown; +ve: positive. From Fabbri LM et al, Eur Respir J 2008 (18).       
 
 
1.4 DIAGNOSIS 
 
1.4.1 HISTORY AND PHYSICAL EXAMINATION  
The symptoms of chronic bronchitis (worsening dyspnea, cough and sputum production) may 
precede by many years the development of airflow obstruction.  
This pattern offers a unique opportunity to identify smokers and other patients at risk for COPD, 
and to intervene when the disease is not yet a major health problem. In the presence of such 
symptoms and signs, a complete anamnestic evaluation should be obtained, including familiar 
history, presence of comorbidities and other respiratory diseases.  
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Particular interest must be reserved to risk factors exposure, especially cigarette smoking, other 
environmental factors and genetic predisposition or working.  
 
1.4.2 SPIROMETRY  
This is the most reproducible and objective measure available of airflow limitation. The 
spirometry should be performed after adequate dose of bronchodilator with short duration of 
action, that reduce the variability of the test. A value of FEV / FVC < 0.70 after bronchodilator 
allows confirmation of persistent airway obstruction.  
 
Figure 1.2 Graph of the curve spirometric flow / volume. In advanced stages of COPD, there is a marked 
reduction in FEV, FVC and maximal expiratory flow in general. The curve flow / volume in the expiratory phase 
flattens out. Even the inspiratory flow undergoes a reduction but less pronounced than that expiratory [19]. 
 
1.4.3 EVALUATION OF GRAVITY DISEASE  
The new GOLD guidelines (Revision 2011) [1] underlines the diagnostic, therapeutic and 
prognostic importance of a more comprehensive assessment of disease severity, through the 
integration of anamnestic and clinical data with spirometry. In previous documents the severity 
of COPD was defined only on the basis of the degree of airway obstruction, assessed by 
spirometry in terms of value compared with the theoretical VEMS:  
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- GOLD 1: Mild, FEV> 80% predicted  
- GOLD 2: Moderate, 50% <FEV <80% predicted  
- GOLD 3: Severe, 30% <FEV <50% predicted  
- GOLD 4: Very Severe, FEV <30% predicted FEV.  
 
One very important aspect is that only a minority of the smoking population (approximately 20% 
of the total) experience the rapid decline in lung function that leads to severe (GOLD-III) and 
very severe (GOLD-IV) COPD. 
 
Fig. 1.3. The natural history of the FEV1 decline in men followed by Fletcher and coll. (3) is shown with the 
GOLD severity stage superimposed as dotted horizontal lines. Modified from Curtis JL et al., Proc Am Thorac 
Soc 2007 (20). 
 
According to the new guidelines, the two parameters are associated with other indices of disease 
severity, in order to quantify the risk of subsequent decline in lung function and mortality with 
greater predictive value. These indices are the severity of symptoms and the risk of 
exacerbations.  
The severity of symptoms is determined on the basis of two questionnaires:  
- the MMRC (british modified Medical Research Council) questionnaire, that assesses the degree 
of dyspnea and correlates with the risk of future mortality.  
- The CAT (COPD Assessment Test), that provides a measure of the deterioration of health 
status in COPD through 8 questions.  
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The risk of subsequent exacerbations is based on the history of similar events recently treated.  
The combination of the different parameters leads to define four groups of COPD patients:  
 
- Group A: low risk, mild symptoms  
- Group B: low risk, severe symptoms  
- Group C: high risk, mild symptoms  
- Group D: high risk, severe symptoms  
 
Figure 1.4 . Graph integrated for the assessment of disease severity according to the guidelines GOLD 
2011 (1). 
 
 
We have to note that patients in GOLD stages 3-4 are at increased risk of hospitalization or 
death, even in the absence of frequent exacerbations. For this reason it is reasonable to include 
these patients in the groups at "high risk".  
 
1.4.4 ADDITIONAL INVESTIGATIONS 
They are useful for diagnostic and especially for patient follow-up and they include: 
1) Radiological investigations (Rx chest in two projections, CT scan), in particular for the 
diagnosis of emphysema and evaluation of its distribution in the lung.  
The radiologic features of emphysema are hyperinflation and hyperlucency of the lung fields, 
destruction of lung parenchyma, flattening of hemidiaphragms, horizontal ribs and presence of 
bubbles.  
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Figure 1.5 Chest x-ray in two projections that highlights the above described features of pulmonary emphysema. 
 
 
2) Measurement of CO diffusion. 
3) Pulse oximetry and blood gas analysis.  
4) Screening for alpha1-AT deficiency  
5) The exercise test (6-minute walking test)  
6) Mixed indices, such as the BODE index, ranging from 0 to 10 [21], in which we evaluate the 
prognostic impact of global factors both pulmonary and extrapulmonary. The BODE index is an 
indicator of mortality risk in patients with COPD and for this reason it is particularly important 
for the decision of inclusion on the waiting list for lung transplantation [21].In fact, subjects with 
a high BODE index (score of 7 to10) show a mortality rate of 80% at 5 years, with a median 
survival of about 3 years, so they should be evaluated for lung transplantation. Patients with a 
BODE score of 5 to 6 would likely not derive a survival benefit from transplantation but may be 
candidates for early referral. 
 
Table 1.2 Parameters for the calculation of the BODE index. BODE index is obtain through the sum of the 
scores of the 4 parameters evaluated. 
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1.5 MORPHOLOGICAL  ASPECTS 
 
The airflow limitation in COPD is a consequence of the functional framework pathological 
characteristic of the disease, which is mainly composed of two aspects: the small airway 
remodeling and pulmonary emphysema [1]. 
Chronic bronchitis is characterized by  hyperemia, swelling, and oedema of the mucous 
membranes, frequently accompanied by excessive mucinous to mucopurulent secretions layering 
the epithelial surfaces and chronic inflammation at histology. Sometimes, heavy casts of 
secretions and pus fill the bronchi and bronchioles. Although the numbers of goblet cells slightly 
increase, the major pathological changes concern the bronchial glands, both in size and mucous 
production. The increased glandular volume can be assessed by the ratio of the thickness of the 
mucous gland layer to the wall between the epithelium and the cartilage (Reid index).  
The Reid index (normally 0.4) is increased in chronic bronchitis, usually in proportion to the 
severity and duration of the disease. The bronchial epithelium may exhibit squamous metaplasia 
and dysplasia. There is marked narrowing of bronchioles caused by goblet cell metaplasia, 
mucus plugging, inflammation, and fibrosis. In the most severe cases, there may be obliteration 
of lumen due to fibrosis (bronchiolitis obliterans). As it was previously mentioned, these 
bronchiolar changes probably contribute to the obstructive features in bronchitis patients. 
The American Thoracic Society defines emphysema as “a condition of the lung characterized by 
abnormal, permanent enlargement of the airspaces distal to the terminal bronchiole, accompanied 
by destruction of their walls” [22]. Fibrosis may be absent or subtle and mild. There are several 
types of emphysema according to its anatomic distribution within the lobule. 
1. Proximal acinar (centrilobular, centriacinar) emphysema is characterized by distension and 
destruction mainly limited to the respiratory bronchioles, with relatively less change peripherally 
in the acinus. This pattern results from scarring and focal dilatation of the bronchioles and 
adjacent alveoli, which lead to an enlarged airspace or “microbulla” in the center of the 
secondary lung lobule. The central or proximal parts of the acini, formed by respiratory 
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bronchioles, are affected, whereas distal alveoli are spared. It is strongly associated with long-
term cigarette smoking and predominantly involves the upper and posterior portions of the lung 
(Figure 1.6a-c). 
2. Panacinar (panlobular) emphysema is characterised by diffuse, bilateral lung involvement in 
which the alveolar ducts as well as respiratory bronchioles are enlarged, causing uniform 
destruction of the alveolar tissue. This pattern is less common than proximal acinar emphysema 
and comprises several conditions including familiar emphysema associated with α1-antitrypsin 
deficiency (AAT) (Figure 1.6b-d). Another key distinction between the two phenotypes of 
emphysema which has recently emerged is the inflammation characteristics [23]. Proximal 
acinar emphysema presents more numerous T-CD4 +, neutrophils, macrophages, but not T-CD8 
+ nor eosinophils. Furthermore we have an infiltration by mast cells, which is predominant in the 
smooth muscle of the airways and in the alveolar wall and correlates with the degree of bronchial 
reactivity [23].  
 
Fig. 1.6 On the left side macroscopic view (a) and histology (c) of centrilobular emphysema. On the right side 
macroscopic view (b) and histology (d) of panacinar emphysema.  
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3. Other forms include distal acinar (paraseptal) emphysema, which affects the periphery of the 
acinus, most often in the upper lobes beneath the pleura, and the irregular emphysema refers to 
airspace enlargement and lung destruction associated with a pulmonary scar. 
 
1.6 PATHOGENESIS OF THE DISEASE 
 
1.6.1 AETIOLOGY 
Risk factors 
Risk factors for COPD include both genetic factors and environmental exposures; the disease 
seems to arise from an interaction between these two types of factors. 
 
- GENETIC FACTORS: the genetic factor that is best documented is a severe hereditary 
deficiency of alpha-1-antitrypsin, a prototype of protein inhibitors of serine proteases.  
This serpin has a major role in inactivating neutrophil elastase and other proteases to 
maintain protease/anti-protease balance [24]. Reduction in anti-elastase defence (which 
might happen with severe deficiency of AAT) can unfavourably tip the elastase/anti-elastase 
balance unfavourably towards accelerated lung breakdown. In addition, AAT has important 
anti-inflammatory properties and this genetic defect could be responsible for the abnormal 
inflammatory response observed in COPD lungs. 
The published COPD genetic association studies have focused on other candidate genes, 
identified by linkage analysis [25]. Variations in candidate genes, which are usually due to 
single-nucleotide polymorphisms (SNPs), have been investigated to detect association with 
COPD susceptibility. 
Candidate genes involved in protease/anti-protease balance, oxidative stress, xenobiotic 
metabolism of toxins, and inflammatory or immune responses have been explored in this 
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field. The candidate genes listed in the following table (Table 1.4) resulted from targeted 
investigations based on linkage studies or pathophysiologic hypotheses [26]. 
 
 
 
TABLE 1.3 Candidate genes, besides AAT, with replicated associations to COPD, emphysema or related 
traits. From Wan ES et al., Chest 2009 (26). 
 
 
- EXPOSURE TO ENVIRONMENTAL POLLUTION: 
 a) Active / passive / in utero cigarette smoking  
This is the main risk factor for COPD. However, not all smokers develop clinically 
significant COPD, which suggests that other cofactors, host-related or not, may modify each 
individual risk. “Susceptible” smokers show a decline in lung function (FEV) of different 
degree, but generally progressive and stronger (60ml/year or more) than not susceptible 
smokers and non-smokers (30ml/year). In addition, smokers have a higher prevalence of 
respiratory symptoms and a higher mortality rate associated with COPD [4].  
The smoke damage is cumulative and it depends on intensity and duration of exposure. The 
injury is due to an increase oxidative stress, resulting in airway epithelial cell damage and 
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activation of pro-inflammatory signals, responsible for recruitment of innate immunity cells 
and the perpetuation of tissue aggression [27,28]. 
b) Occupational dusts and chemicals. 
Occupational exposures include organic and inorganic dusts and chemical agents and fumes. 
A statement published by the American Thoracic Society concluded that occupational 
exposures account for 10 to 20% of either symptoms or functional impairment consistent 
with COPD [29]. 
c) Indoor and outdoor air pollution. 
There is evidence that indoor pollution from burning biomass fuels for cooking and heating 
is an important cause of COPD in many developing countries [30,31], but the exact 
pathogenetic mechanisms have not yet been elucidated. 
 
Other recognized risk factors are:  
- Altered growth and development of respiratory system: a low weight birth is associated 
with reduced values of lung function indices (FEV) in adulthood, implying a state of 
incomplete development of the respiratory system [32]. In addition, numerous studies have 
demonstrated the effect of pediatric recurrent respiratory infections on the risk of subsequent 
decline of FEV.  
- Sex: historically COPD hits the males, as they are more exposed to cigarette smoke. The 
incidence and prevalence of the disease in women is growing, with the increase in smoking 
in recent decades [33]. 
- Age and ageing: epidemiological studies show that prevalence and impact of the disease 
increased with age [5]. Nevertheless, it is unclear whether aging is itself a risk factor for the 
disease or whether this association is an expression of cumulative and prolonged exposure to 
traditional risk factors. 
  25 
- Respiratory And Systemic Infections: tuberculosis is a risk factor for the development of 
COPD. On the other hand it is seen that HIV infection accelerates the onset of emphysema 
smoke-related [34].  
- Socio-Economic Status: There is a strong evidence of an inverse relationship between 
socioeconomic status and the risk of developing COPD, but the factors responsible for this 
association are not clear [35].  
- Asma: A longitudinal study (Tucson Epidemiological Study of Airway Obstructive 
Disease) has shown that adults with asthma have a RR = 12 to develop COPD than non-
asthmatics, adjusted for smoking status [36].  
- Chronic Bronchitis: the study of Fletcher and colleagues showed that chronic bronchitis 
was not associated with decline in lung function [4]. Subsequent studies, however, have re-
evaluated the role of mucus hypersecretion in the decline of FEV and the existence of an 
increased risk of developing COPD in young adults who smoke and who are suffering from 
chronic bronchitis [36]. 
 
1.6.2 PATHOGENETIC MECHANISM  
Despite advances in care to date there are no therapies which  halt or reverse the progressive and 
accelerated decline in lung function of this condition. Better means of preventing and treating 
COPD are urgently needed and a better understanding of the pathological bases is a necessary 
requirement. 
The discovery of the AAT deficiency in the 60s led to the hypothesis that an imbalance between 
proteases and antiproteases in the lung could be the cause of lung damage in all COPD patients 
[37]. Smoking induces an increased number of neutrophils and macrophages in the lung and the 
release of proteolytic enzymes from these cells. The released proteases, not fully inhibited by 
antiproteases, lead to proteolysis of lung connective tissue (more specifically of elastin) and 
emphysema. However, the pathogenetic view of COPD has expanded significantly from what 
was understood in past decades. Moving beyond the original protease/antiprotease hypothesis, T-
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lymphocytes have been identified as a key component of the inflammatory response, thus 
introducing the concept that adaptive immunity may be centrally involved in the pathogenesis of 
the disease [38]. Indeed, recent studies have convincingly shown that emphysema can be 
produced in experimental models, not only by manipulation of proteolitic pathways, but also 
targeting CD8 T-cell responses [39]. Distinctive immune features, such as lymphoid follicles 
rich in B and T cells are found in lung tissue of patients with COPD, at least in the severe stages 
of the disease [40]. Altered T and B cell responses are also seen in the peripheral blood of 
patients with COPD, indicating that immunological alteration extends beyond the lung.  
Despite the well documented presence of inflammation in COPD, it is unclear what steps are 
involved in  the genesis and progression of the disease. The new concept emerging from the most 
recent observations, to which substantial contribution was gives by our group, is that persistence 
of the immune activation in COPD could be due to an autoimmune reaction secondary to the 
lung damage triggered by cigarette smoking (Fig. 1.7) [41]. Cigarette smoking can damage the 
epithelium and the products of epithelial cell injury can stimulate the innate immune response, 
acting as ligands for Toll like receptors (TLRs), especially TLR-4 and TLR-2.  
 
Fig. 1.7. Initial Response to Cigarette Smoke — Step 1 
Cigarette smoke injures epithelial cells, which release “danger signals” that act as ligands for toll-like 
receptors (TLRs) in the epithelium. These actions trigger the production of chemokines and cytokines, 
which results in an innate inflammation. Products from the inflammatory cells may injure the 
extracellular matrix, leading to the release of TLR ligands and consequent TLR activation, which will 
promote further inflammation, tissue injury, and the production of antigenic substances. This chain of 
events may cause dendritic cells to mature and migrate to local lymph organs, where, if the conditions 
are favorable, T-cell activation may result, with progression of the disease. If the innate inflammation in 
step 1 is minimized or controlled, the inflammation will not progress to adaptive immunity, and the 
disease may be arrested. These processes are typical of smokers who have neither COPD nor Gold stage 
1. GM-CSF denotes granulocyte–macrophage colony-stimulating factor, HSP heat-shock protein, ICAM-
1 intercellular adhesion molecule 1, MCP-1 monocyte chemoattractant protein 1, and TNF tumor 
necrosis factor. 
From Cosio MG et al., N Engl J Med 2009 (41). 
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Fig. 1.7. Proliferation of T Cells — Step 2 
When step 1 is successful, mature dendritic cells migrate to local lymphatic organs, whereupon 
stimulation by toll-like receptors (TLRs) leads to the expression of CD80–CD86 and cytokines, creating a 
propitious milieu for T cell antigen presentation and proliferation into effector CD4+ type 1 helper (Th1) 
T cells and cytolytic CD8+ T cells. Interleukin-6, secreted by the dendritic cells, favors the production of 
effector T cells by overcoming the signals from regulatory T (Treg) cells. Upon activation, effector T cells 
express tissue- specific chemokine receptors. Immune regulation or tolerance mechanisms will determine 
at this stage the degree of proliferation of T-cell effectors, homing, and eventually, disease severity. An 
absence of tolerance is associated with Gold stage 3 or stage 4, moderate tolerance with Gold stage 2, 
and full tolerance with Gold stage 1. MHC denotes major histocompatibility complex. 
From Cosio MG et al., N Engl J Med 2009 (41). 
 
 
The subsequent activation of alveolar macrophages and neutrophils, with their array of 
proteolytic enzymes, further damage the lung tissue disrupting the extracellular matrix and the 
resulting breakdown products, such as hyaluronate and bicyclan, can also ligate TLR- and TLR-
4. In support of this proposed pathway is the finding in mice that lung inflammation induced by 
cigarette smoke depends on TLR-4 and MyD88, an adapter protein that stimulates NFκB [42]. 
These processes would result in release of normally sequestered autoantigens (proteins and DNA 
that may undergo modifications) which the adaptive immune system can recognize as foreign 
antigens triggering an immune reaction (Fig. 1.8).  
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Fig. 1.8. The Adaptive Immune Reaction — Step 3 
Inflammation (autoimmune) develops in the lung, consisting of CD4+ type 1 helper (Th1) T cells, 
cytolytic CD8+ T cells, and IgG-producing B cells. Regulatory T cells (Treg) and γδ CD8+ T cells could 
modulate the severity of the adaptive immune inflammation. The resulting immune inflammation, induced 
by CD4+ Th1 T cells and consisting of activated innate immune cells producing oxidative stress and 
proteinases, along with cytolytic CD8+ T cells and B cells, leads to cellular necrosis and apoptosis, 
immune and complement deposition, tissue injury with airway remodelling, and emphysema, as well as 
the release of additional antigenic material, which perpetuates the process. In step 3, the full autoimmune 
process has developed, producing the most severe disease (Gold stage 3 and stage 4). NO denotes nitric 
oxide, and ROS reactive oxygen species. 
From Cosio MG et al., N Engl J Med 2009 (41). 
 
 
In this context some important cytokine may be involved to disease development and 
progression. 
One of these is interleukin-32 (IL-32), which role may be of potential interest. IL-32 is a pro-
inflammatory cytokine, which is upregulated in autoimmune diseases such as rheumatoid 
arthritis [43] and Chron’s disease [44]. The cytokine has important functions in innate and 
adaptive immune responses. It synergizes with NOD1 and NOD2 ligands to stimulate IL-1β and 
IL-6 release in a caspase-1-dependent manner. Proteinase 3 (PR3) is a specific IL-32 binding 
protein which cleaves the cytokine to enhance its activity. Interestingly, AAT is the main 
inhibitor of PR3 [45]. There is evidence that viral stimuli (influenza A or double-stranded RNA 
[poly(IC)] + IFN-γ) may trigger IL-32 expression and that cigarette smoke can potentiate the 
lung responses caused by these stimuli.  
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Of interest, we recently reported an increased expression of IL-32 in lung tissue of patients with 
COPD, where it was co-localized with TNFa and correlated with the degree of airflow 
obstruction, suggesting that IL-32 could be a potentially useful biomarker to evaluate the 
progression of the disease [46].  
 
1.7 LUNG CANCER 
 
Lung cancer is currently the leading cause of cancer death in the world with a 5-year survival of 
about 15%, despite the use of increasingly aggressive therapies [47]. Currently, lung cancer has a 
maximum incidence between 55 and 65 years and it is responsible for 32% of total deaths for 
cancer in men and 25% in women [47]. This high mortality closely linked to the characteristics 
of the tumor and to the delay in diagnosis of this disease which presents a rather low percentage 
of patients (approximately 20%) with early stage cancer. 
The World Health Organization has included in the new classification of lung cancer 4 main 
histological types [48]; however, under therapeutic and prognostic purposes the most useful and 
widespread differentiation of lung cancer involves two major groups, defined as small cell lung 
carcinoma (SCLC) and non-small cell lung cancer (NSCLC).  
Small cell lung cancer is a extremely malignant tumor, with a very high mortality rate and 
molecular pathogenic pattern completely different from NSCLC. 
The NSCLC category can be divided in different histological types, among which the most 
important are the squamous cell carcinoma and the adenocarcinoma. 
The adenocarcinoma classification was recently revised [49] with the abolition of the 
bronchioloalveolar carcinoma and mixed subtype adenocarcinoma. By contrary, invasive 
adenocarcinomas are classified by predominant pattern after using comprehensive histologic 
subtyping with lepidic, acinar, papillary, and solid patterns. 
Adenocarcinoma incidence is increased in the last two decades, in parallel with the decrease in 
the incidence of squamous form [47]. In Europe, they account for 30% of bronchopulmonary 
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carcinomas while in North America they already are the most common histological type (about 
50%). The increased incidence is probably related to the use of filter cigarettes and the 
consequent reduction in the size of the particulates and increase of nitrates. It has also been 
described the association with pre-existing lung scars caused by eg tuberculosis or pulmonary 
infarcts. 
Worldwide, tobacco smoking is associated with more of 90% of cases of lung cancer [47] . In 
more developed countries, the incidence and mortality rates are generally declining, reflecting 
previous trends in smoking prevalence. However, in less developed countries lung cancer rates 
are predicted to continue to increase due to endemic tobacco use [50] . There is a clear role for 
genetics since only 15% of lifetime smokers develop lung cancer and 10% of lung cancers occur 
in never-smokers especially in women [51] and in Asiatic women in particular [52] . 
One important hypothesis in these categories of patients is the presence of a genetic background 
that can predispose to lung cancer in the absence of external environmental pollutants [52]. 
In this field the two most important recognized oncogenes in tumour developing and growing are 
EGFR e KRAS. 
Epidermal growth factor receptor (EGFR or ErbB-1) is a tyrosine kinase receptor belonging to 
the ErbB family; it is widely expressed in NSCLC (40-80% of NSCLC) and plays a significant 
role in carcinogenesis through improper activation of EGFR Tirosin-Kinase (TK) domaine which 
results in increased malignant cell survival, proliferation, invasion and metastasis. The TK 
activity of EGFR may be dysregulated by various oncogenic mechanisms, including the presence 
of harbored mutations in the TK domain of EGFR [53-55]. Overall, the frequency of EGFR 
mutations is 5–20%, depending on the populations studied [56]. 
RAS is one of the important molecules in the downstream of EGFR signaling pathway. Wild-
type forms of ras proteins have GTPase activity and their activation is strictly dependent on the 
bond with alternative forms of GDP (inactive) or GTP (active), allowing tight control of signal 
transduction [57]. These proteins acquire oncogenic function through point mutations at codons 
12, 13, or 61 of exon 2 that abolish the GTPase function giving therefore a constitutionally active 
  31 
conformation and deregulating thereby cell proliferation. For these reasons mutated Ras genes, 
especially K-ras, observed among 20~30% NSCLC patients, have been implicated in the 
pathogenesis and prognosis of lung cancer [58]. 
In 1991 Slebos and after ten years Ahrendt found that k-ras mutations are found almost 
exclusively in patients with lung adenocarcinoma and smoking history. In addition, Feng 
reported that exposure to this carcinogen induces alterations at the codon 12 of K-ras in the 
human bronchial epithelium, suggesting a direct molecular mechanism of smoking in human 
lung carcinogenesis. Moreover NSCLC patients with K-ras mutations are associated with 
unfavorable prognosis [59].  
Concerning lung cancer treatment, surgery actually represents the cornerstone of therapy for 
NSCLC even if global resectability still ranges from 10 to 25% [60]. With strict pre-operative 
selection criteria, the healing rate in patients undergoing complete resection for NSCLC in early 
stage (I-II) ranges between 40 and 70% [61]. However, even in these cases, the possibility of 
loco-regional and/or distance recurrences is not an uncommon event, representing the main 
factor affecting long-term survival. 
For this reason, the use of integrated approaches with adjuvant regimen of chemo- and / or 
radiotherapy has been recently introduced even in early stages in order to reduce this risk [62].  
These integrated approaches have enabled a further increase in 5 year overall survival, but 
according to most authors, new therapeutic protocols based on traditional chemotherapy does not 
seem to offer further opportunities for improvement of results [63]. 
In addition to their carcinogenic activity, EGFR and KRAS have emerged as two of the most 
relevant targets for cancer treatment. 
Gefitinib and erlotinib are small-molecule reversible tyrosine kinase inhibitors (TKIs) that 
selectively target EGFR. The presence of somatic mutations in the tyrosine kinase domain of 
EGFR (exon 18-21) involving the ATP-binding pocket of the receptor was shown to represent 
the most important predictive marker [53-55]. For these patients, the response rate to gefitinib 
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and erlotinib is approximately 75%, suggesting that these mutations, at least in part, drive 
malignant transformation [56,64]. 
In contrast, somatic mutations in exon 2 (codon 12-13) of KRAS have been associated with 
primary resistance to EGFR inhibitors. EGFR and KRAS mutations seem to be mutually 
exclusive, which is consistent with the idea that different alterations of the same pathway are 
involved in lung carcinogenesis [65]. 
Regarding lung cancer long-term results, TNM staging system [66], is currently the most 
important and accurate prognostic instrument. However, it still presents significant difficulties in 
predicting the effectively outcome of individual patients. Some authors has recently proposed the 
use of PET-CT scan, and in particular the maximum standard uptake value (SUVmax), as new 
tool to predict tumor biologic aggressiveness [67]. It is therefore understandable how a greater 
knowledge of molecular and histological cancer phenotypes associated to patient characteristics, 
able to predict individual outcomes and treatments, is therefore desirable. 
 
1.8 COPD AND LUNG CANCER 
 
It is becoming increasingly evident that COPD and lung cancer are strictly related.  
Indeed COPD has recently established as important risk factor for developing lung cancer, even 
independently from the effects of smoking. Indeed, it has been shown that the risk of lung cancer 
is increased in smokers with COPD up to 6-fold compared to smokers with comparable cigarette 
exposure, but without COPD [68,69]. It has also been shown that the presence of COPD 
increased lung cancer mortality even among nonsmokers [70]. 
In addition, lung cancer is also a leading cause of morbidity and mortality in patients with COPD 
as 33% of patients died of lung cancer over a 14.5-year follow-up [71]. Furthermore 50–70% of 
patients diagnosed with lung cancer have spirometric evidence of COPD [72]]. As a practical 
consequence of the epidemiological associations between COPD and lung cancer, an important 
question is whether the relationship between lung cancer and COPD is subtype specific. A small 
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case – control study [73] showed that airflow obstruction is primarily a risk factor for squamous 
cell lung cancer (odds ratio = 3.49, 95% CI = 1.63 to 18.5; P = .006), whereas symptoms of 
chronic bronchitis without COPD is a risk factor (risk greater than fourfold) for adenocarcinoma 
of the lung. In a subset analysis, having concurrent bronchitic symptoms and COPD was 
associated with a more than threefold increased risk for squamous cell carcinoma. Despite these 
striking epidemiological associations, the mechanisms by which COPD can be linked to lung 
cancer are poorly understood.  
 
1.8.1 Risk factors 
Primarily, the main risk factor for the onset of both diseases is cigarette smoking, but they 
probably also share a common familial component and environmental risk factors other than 
smoking. This supposition is reinforced by the fact that  only a fraction of smokers (around 15%) 
will develop lung cancer and/or COPD in their lifetime [1,74] which suggests a different 
individual susceptibility to the risk of lung cancer and/or COPD or time of disease onset. 
Some common elements in the pathogenesis of COPD and lung cancer include oxidants, familiar 
and genetic predisposition (p53, Rb, K-ras), peptides and endopeptidases (bombesin-like), 
dysregulation of growth factor expression and among others inflammation.  
While the mechanism of cigarette smoking damage in COPD has been previously treated, for 
lung carcinogenesis, the action is probably related to DNA mutations induction.  
Carcinogenesis is a complex process characterised by the accumulation of multiple independent 
genetic alterations, often involving overexpression of oncogenes and loss of tumour suppressor 
genes. These genetic alterations disrupt the normal regulation of cell signalling pathways, 
essential for the control of cell growth, differentiation and apoptosis [75]. The observation of 
familial aggregation of emphysema dates back more than 200 years, and studies conducted 30 
years ago reveal a familial aggregation of lung cancer associated with COPD that is not 
explained by α1-antitrypsin genotype or smoking history [76,77]. Familial aggregation is well 
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documented for multiple cancers, although it has been difficult to separate the contributions of 
genetic differences and environmental exposures in the development of lung cancer.  
A number of linkage studies [78] have investigated genes involved in both lung function and 
COPD and candidate susceptibility genes involved in COPD and lung cancer. These studies have 
led to the identification of markers on chromosome 6q for lung cancer and abnormal lung 
function and on chromosome 12 for lung cancer, COPD, and lung function, as well as numerous 
other candidate susceptibility genes involved in detoxification, immune regulation, matrix 
remodeling, DNA repair, cellular proliferation, and tumor suppression [78]. Among the genetic 
connections between COPD and lung cancer, it is particularly interesting to note that both the Z 
and the S alleles of the α1-antitrypsin gene are more common in patients with lung cancer 
compared with the general population, as is a polymorphism in the neutrophil elastase gene 
[79,80], suggesting that an imbalance between neutrophil elastase and α 1-antitrypsin may 
contribute to the development of both COPD and lung cancer [81].  
The role of epigenetic modifications in the common pathogenesis of COPD and lung cancer also 
deserves attention.  
Although there is growing evidence implicating DNA methylation, histone deacetylation, and 
protein phosphorylation in lung cancer pathogenesis [82,83], this knowledge is only now being 
applied to COPD, alone or when associated with lung cancer [84].  
It is plausible that several candidate risk genes and pathways identified by lung cancer studies 
may be shared by these two diseases and could constitute potential targets for the newly 
developed drugs (eg, demethylating agents and histone deacetylase – inhibiting agents) that 
modify epigenetic alterations.  
The inflammatory paradigm is undoubtedly one of the most fascinating theories to connect 
COPD and lung cancer and it has acquired new impetus by the recent discoveries in the COPD 
pathogenesis. 
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1.8.2 The inflammatory theory 
As described above, COPD is characterized by the accumulation of macrophages, CD4+ and 
CD8+ T cells, dendritic cells, B cells and neutrophils, particularly in smaller airways and lung 
parenchyma, and the severity of COPD is associated with the degree of infiltration by these 
inflammatory cells [1]. 
Moreover, chronic inflammation may play a significant role in the pathogenesis of lung cancer as 
a tumour promoter. A causal relation between inflammation and cancer was initially proposed by 
Galen and later by Virchow [85], who noticed the infiltration of leucocytes in malignant tissues 
and suggested that cancers arise at regions of chronic inflammation.  The hypothesized 
carcinogenetic mechanism in COPD patients states that cigarette smoke initially creates a direct 
parenchimal damages that up-regulates the cytokines production, such as interleukin (IL)-1b, and 
the Th-1 cytokines, which can promote the inflammatory response through typical COPD T-
lymphocytes and finally resulting in an overproduction of cytokines, such as IL-6, IL-8, and IL- 
10. Some of the latter mediators can inhibit apoptosis, interfere with cellular repair, and promote 
angiogenesis. All in all, chronic inflammation may play a pathogenic role in lung cancer by 
amplifying the initial mutagenic damage and enhancing both tumour growth and metastasis. IL-
8, for example, has been shown to be pro-oncogenic, such as releasing BCL-2, but also 
suppresses oncogenes, such as p53, hence minimizing apoptosis while inducing cell 
transformation. In addition, among mechanisms that regulate the progression or suppression of 
tumor growth, the role of cellular senescence is becoming increasing appreciated. Cellular 
senescence permanently arrests cell growth in tissues at risk for malignant transformation, 
particularly those that experience prolonged inflammation, such as the airways and the lung 
parenchyma in smokers with COPD. On the other hand, senescent cells undergo profound 
modifications which can have deleterious effects on the tissue microenvinronment. The most 
significant of these alterations is the acquisition of a senescence-associated secretory phenotype 
(SASP) that promotes the secretion of several proinflammatory cytokines (particularly IL-6 and 
IL-8), growth factors and metalloproteinases, which could eventually promote tumor progression 
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and invasiveness. Of note, senescent cells have the ability to influence the populations of 
macrophages and lymphocytes infiltrating nascent tumors, shifting the balance from cell 
populations associated with tumor suppression (M1 macrophages, Th1 T-lymphocytes) to those 
that instead promote tumor progression (M2 macrophages, Th2 and T regulatory lymphocytes). 
The mechanism of perpetuation of damage typical of COPD could also explain in these patients 
the risk of lung cancer irrespective of active smoking [70]. In fact, after quitting smoking, lung 
cancer risk remains increased in patients with COPD, though this risk is superior in those who 
continue to smoke [70].  The close connection between COPD, inflammation, and lung cancer is 
even more apparent in light of recent findings that point to a possible relationship between 
inhaled corticosteroids and reduced lung cancer risk in COPD patients [86,87].  
Complementary to this is the observation that the incidence of lung cancer is associated with 
specific stages of COPD severity. Lung cancer is assigned as the cause of death in 33% of 
patients with mild-to-moderate COPD with a decreased in patients with more severe disease 
[88,89]. 
According to this data, in our experience we did not observed cases of lung malignancy in 
patients with end-stage COPD candidates to lung transplantation, differently from other end-
stage chronic inflammatory diseases such as scleroderma, sarcoidosis and especially pulmonary 
fibrosis.  
For these reasons our research group has proposed a pathogenetic hypothesis that, in agreement 
with recent autoimmune theory, attributes to the peculiar inflammatory phenotype of COPD 
advanced stages  a protective and surveillance role against neoplastic development. 
As previously reported, the T regulatory cells and the associated cytokine pattern play a strategic 
role in the interaction between COPD and lung cancer, although a complete understanding of the 
process is still far away. 
In this field, the analysis of TH17 cells and the IL17 cytokine  could really represent the link 
between these two important diseases. 
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1.8.3 Pathway axys IL17- R23 
Th17 cells are a critical component of the adaptive immune response and have also been 
implicated in chronic inflammatory diseases and autoimmune diseases [90], although their 
primary function appears to be the clearance of pathogens that are not adequately handled by 
Th1 and Th2 cells, especially extracellular bacteria and fungi [91]. The cytokine 
microenvironment influences the differentiation of naive T cells into Th17 cells. The Th17 
lineage depends on the presence of TGF-b1 and IL-6, found in elevated concentrations 
particularly in chronic obstructive pulmonary disease (COPD) [92].  
In effect, an increase in Th17 cells was observed in patients with COPD compared with current 
smokers without COPD and healthy subjects. Human Th17 cells differ from other cell subsets in 
their potency to induce proinflammatory cytokines in bronchial epithelial cells, airway 
fibroblasts and smooth muscle cells and above all they secrete the cytokine IL-17 [93], which 
plays an important proinflammatory role in COPD.  
The IL-17 family comprises of six members (IL-17A–17F) [94] and five receptors (IL-17RA–
17RE) [95].  
IL-17RA is the largest member of the IL-17R family and at least four ligands are mediated 
through this subunit [96].  
The expression of IL-17RA is up-regulated by cytokines such as IL-15 (produced by a range of 
non-T-cells, including macrophages and IL- 21 [97] on CD8+ T-cells, and so may play an 
important role in COPD. 
IL-23 plays a key role in the maintaining and expanding the Th17 cell lineage over time to 
release IL-17 [98] and is secreted from APCs such as dendritic cells. IL23 is released in response 
to inflammatory signals and therefore is continually expressed in chronic inflammation. 
 IL-17 induces epithelial cells to produce antimicrobial peptides (such as b defensins) and 
numerous chemokines, such as TNF-a, IL-1b, IL-6, GM-CSF, granulocyte colony-stimulating 
factor and IL-8 [99]. All these findings clearly indicate that IL-17 is able to generate an 
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intriguing crosstalk between the adaptive and innate immune systems, regulating an efficient 
immune response (Fig. 1.10) [100].  
Many studies found an increased production of IL-17, especially IL-17A in COPD patients 
although its  involvement in the development of COPD is poorly understood [101].  
 
Fig. 1.10. Schematic representation of the balance between Treg-cells and Th17 cells in COPD. The type of 
immune response activated relies on the cytokine environment and the individual’s immune system, leading to 
varied clinical outcomes. In some situations, there can be a switch of lineage from Treg-cells to Th17. TGF-β and 
IL-6 are crucial in the transition between lineages (From Lane N.  (102). 
 
 
In recent years, Th17 cells and IL-17A have been also associated with various human tumors, 
including NSCLC [103-105].  In particular the number of Th17 cells detected in tumors has been 
shown to positively correlate with microvessel density, as well as it was observed that high 
levels of IL-17A expression in tumor cell lines promoted angiogenesis, limphangiogenesis and 
cell proliferation [106]. The action of IL-17 seems closely related to induction of VEGF. In fact, 
Li [107] has shown that the elevated expression of this growth factor in supernatant of 
adenocarcinoma cell lines were IL-17a concentration-dependent. In addition he found higher 
serum levels of IL-17a in patients with lung adenocarcinoma compared to healthy controls and 
higher positive expressions of IL-17a, IL-17Ra and VEGF in lung adenocarcinoma lesion tissues 
than pericancerous normal tissues.  
Liu [108] has recently proposed a new potential mechanism of lung carcinogenesis for IL-17 
through  the formation of an M2-macrophage–dominant tumor microenvironment in non–small-
cell lung cancer. Based on the finding that lung tumor tissues expressed significantly higher 
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levels of IL-17 and prostaglandin E2 (PGE2) than normal lung tissues, he speculated on the 
possibility that IL-17 served as a chemoattractant to recruit macrophages into the lung tumors 
while PGE2 induced differentiation of M2 macrophages. 
Based on these fundamental premises, lung cancer associated with COPD seems to possess 
specific pathogenetic and morphological features, differently from cancers resulting from simple 
smoke damage. 
Therefore, a better understanding of these phenotypes could lead to important consequences of 
great relevance in therapy and care of patients affected by COPD and lung cancer. 
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2. AIM OF THE RESEARCH 
 
 
This research project focuses on the study of lung cancer in patients with COPD compared to 
control groups, composed by healthy smokers and non-smoking patients in order to identify 
eventual distinct biohumoral, morphological and molecular phenotypes.  
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3. MATERIALS AND METHODS 
 
 
3.1 STUDY POPULATION 
 
From January 2010 to December 2012 we prospectively enrolled in the study patients submitted 
to anatomical surgical resection for non small cell lung cancer (NSCLC) in the Thoracic Surgery 
Unit of Padua and Strasbourg. 
Inclusion criteria were the follows: 
- Patients undergoing major resections (lobectomy or pneumonectomy) associated with 
hilar-mediastinal lymphadenectomy; this decision was motivated from the need to have 
sufficient non neoplastic lung parenchyma to study the peri-neoplastic tissue remodeling. 
- Patients with peripheral lung nodule. 
- Patients with suspected or known primary NSCLC.   
 
Exclusion criteria were the follows: 
 
- Patients with inflammatory lesion or with metastatic pulmonary cancer. 
- Patients with NSCLC involving central airways in order to avoid distortions of lung 
architecture or presence of local and/or systemic inflammatory reactions. 
- Patients with chest wall involvement. 
- Patients previously treated by chemo and / or radiation therapy. 
- Past history of asthma or allergic rhinitis and acute upper respiratory tract infections. 
- For COPD patients, presence of exacerbations during the month preceding surgery. 
All patients included in the research project  were subjected full clinical/biohumoral and 
functional analysis.  
 
  44 
Clinical study 
For each subject a detailed medical history with particular attention to respiratory symptoms, 
smoking history, concomitant medications and comorbidities was collected.  
Venous blood samples, preserved in Ethylene Diamine Tetraacetic acid, were sent to the central 
laboratory to evaluate the levels of erythrocyte sedimentation rate and C-reactive protein as 
known systemic inflammation signs.  
All subjects underwent pulmonary function tests  (PFTs) that were performed and evaluated by 
an expert pneumologist following the most recent guidelines [109].  
Briefly, the following parameters will be measured: vital capacity (CV), inspiratory capacity 
(IC), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1 to 
FVC ratio (FEV1/FVC), functional residual capacity (FRC), residual volume (RV) and total lung 
capacity (TLC). To assess the reversibility of the airway obstruction in subjects with a baseline 
FEV1/FVC <70 %, measurements will be repeated 15 minutes after the inhalation of 400 µg of 
salbutamol. The diffusing capacity for carbon-monoxide (DLCO) will be assessed using the 
single breath technique. 
Arterial haemogasanalysis was performed to investigate gas exchange (oxygen partial pressure-
PaO2, carbon dioxide partial pressure-PaCO2 and haemoglobin saturation-SHb).  
A complete radiological assessment, including chest-x ray, Chest and Abdomen CT scan was 
performed in every patients both for oncological and research reasons. 
In addition patients routinely underwent 18FDG PET-CT scan with measurement of primary lung 
tumor maximal standard uptake value (SUVmax), that is SUV on the highest image pixel in the 
parenchymal tumor regions.      
In all patients bronchoscopic examination with bronchoalveolar lavage (BAL) was carried out. 
BAL, blood and fresh cancer tissue were preserved in frozen tissue bank for future 
immunohistochemical and molecular studies.  
The collection and preservation of biological materials for frozen bank followed the guidelines 
of Regione Veneto and Azienda Ospedaliera di Padova. 
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Patients enrolled in the study were then divided in 3 groups according to respiratory functional 
tests and smoking history: COPD patients, smoker patients without COPD and never-smoker 
subjects (with normal lung function). 
COPD subjects were identified by the presence of fixed airflow limitation (forced expiratory 
volume in the first second (FEV1) to forced vital capacity (FVC) ratio < 70%). They will be 
subsequently staged on the basis of FEV1 values discriminating smokers with severe COPD 
(FEV1<50% predicted) from those with mild/moderate COPD (FEV1>50% predicted).  
 
3.2 SURGICAL PROCEDURE AND LUNG SAMPLING 
 
As previously reported, every patient underwent an anatomical resection associated with 
systematic limphadenectomy.  
Immediately after the surgical procedure, samples from the nodule and at least three from non-
tumour subpleuric area (2 cm3) were preserved in RNAlater® and then stored in liquid nitrogen 
for molecular studies.  The rest of lung parenchyma was sent to the Pathological Anatomy 
Laboratory and perfused using 4% formaldehyde via bronchial tree with constant pressure of 25 
cm  of water (Fig. 3.1). 
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Fig. 3.1. Intra-operative view of a lobe specimen after resection with bronchial incannulation to 
perform selective perfusion using 4% formaldehyde with constant pressure of 25 cm  of water.  
 
The lung was then taken in a large container of formalin for at least 24 hours. This method of 
lobe perfusion allowed to obtain adequate lung samples for microscopic and morphometric 
diagnosis, avoiding on the one hand emphysema overestimation due to alveolar hyperdistensions 
and from the other areas of parenchymal atelectasis. Four samples were taken both from 
neoplastic areas and non neoplastic sites. After dehydration, samples will be embedded in 
paraffin and serial sections were cut for histological, immunohistochemical and molecular 
studies.  
 
3.3 HISTOLOGICAL ANALYSIS 
 
All histological and immunoistochemical parameters were blindly evaluated by the same 
pathologist (FC)  
  47 
3.3.1 Pathological diagnosis 
Tissue sections were stained with haematoxylin and eosin  and Masson’s stains. Histo-
pathological evaluation of the tumor were done by an expert Pathologist according to the latest 
revision of lung cancer classification [48]: in particular, in case of  adenocarcinoma, a precise 
quantification of the different histological pattern (lepidic, acinar, papillary and solid) percentage 
was done [49].  
pTNM staging was conducted in accordance with the 7th edition of 2009 [66]. 
 
3.3.2 Morphological evaluations 
In all neoplastic lesions were evaluated and quantified the following parameters: 
- Inflammation, necrosis and fibrosis were quantified by an expert pathologist in 
peritumour and intratumour areas and the amount was expressed both semiquantitatively 
using  a score system from 0 to 3 (no positivity, 0; mild, 1; moderate, 2; strong, 3) both as 
percentage of extension:1: <30% of neoplastic and perineoplastic areas; 2: from 30 to 60% 
and 3>60%. 
- Four µm-thick sections were cut and processed for immunohistochemical analysis of ki-
67.  Briefly after dewaxing and hydration, sections were incubated in citrate buffer 5 mM at 
pH 6.0 in a microwave oven for 30 min for antigen retrieval. Afterwards, sections were 
treated with blocking serum (Ultratech HRP Kit, Immunotech, Beckman Coulter, USA) and 
incubated for 60 min with the primary monoclonal antibody anti-ki-67 (MIB-1, Immunotech, 
Marseille, France) at a concentration of 1:50. Sections were subsequently incubated with a 
secondary biotinylated antibody for 10 min and then with streptavidin-biotin complex 
conjugated to horseradish peroxidase for 10 min (Ultratech HRP Kit, Immunotech, Beckman 
Coulter, USA). Immunoreactivity was visualized with diaminobenzidine (DAB, Dako, 
Glostrup, Denmark). Finally, the sections were counterstained with Mayer’s hematoxylin. 
Negative controls for nonspecific binding were processed omitting the primary antibodies and 
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revealed no signal. Ki-67 positivity was evaluated by using an assisted computerized 
morphometric analysis counting at least 100 cells in the most representative areas. Data were 
expressed as number of positive cells/total cell count % and ki-67 quantification represented 
the ki-67 labeling index.  
3.3.3 Characterization of the peri-and intra-tumor IL-17 cytokine pattern  
For immunohistochemistry, deparaffinized sections were treated with 3% hydrogen peroxide in 
phosphate-buffered saline (PBS) for 10 minutes and incubated for 30 minutes at 90°C for antigen 
retrieval. Next, the specimens were individually incubated for 12 hours at 4°C with the 
polyclonal antibody diluted in 2% bovine serum albumin before use anti–IL-17 (1:100) 
(AbCAM). The sections were washed and incubated with the streptavidinperoxidase conjugate 
(Dako) for 30 minutes.  
The slides were washed with HRP labeled polymer anti-rabbit (Dako) for 30’ and 
immunoreactivity was visualized with 3-3’-diaminobenzidine (Dako). Negative controls for 
nonspecific binding were processed omitting the primary antibody and revealed no signal.  The 
sections were counterstained with hematoxylin. 
Data were expressed using a  combined score from staining intensity ( graded with score 1: mild, 
score 2: moderate, and score 3: strong ) and percentage of positive cells. 
 
3.4 GENETIC ANALYSES 
 
All paraffin-embedded samples were evaluated by a pathologist in order to assess the tumour 
tissue quality and quantity. Molecular analysis was performed when the tumour tissue comprised 
more than 50% of the entire sample. DNA was extracted using a QIAmp DNA kit (Qiagen, 
Milan, Italy), according to the manufacturer’s instructions. Agarose gel electrophoresis was used 
to control its quality and quantification was performed by spectrophotometry. 
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A total of 100 ng of genomic DNA was used for polymerase chain reaction (PCR) to amplify 
exons 18, 19, 20, 21 of EGFR gene and exon 2 of KRAS gene by using primers, sequences and 
amplification conditions according to previous studies (8, 17). PCR products were purified using 
a pre-sequencing kit (Amersham Biosciences, Little Chalfont Buckinghamshire, UK). 
Subsequently, they were sequenced with both forward and reverse primers using BigDye 
Terminator v1.1. Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). 
Automated sequencing was carried out using an ABI 3130xl DNA sequence (Applied 
Biosystems). 
 
3.5 ELECTRONIC DATABASE 
 
A multidisciplinary electronic database (Excel, Microsoft Office Professional 2007) was built 
following the privacy rules.The database contains all the clinical, radiological, functional, 
pathological and molecular data and was used for statistical analysis. 
The database did not include any personal identification label and was held in secure password 
protected storage under the responsibility of the Unit Coordinators (Prof. Rea, Prof. Saetta and 
Prof. Calabrese) in accordance with the requirements of the Health Information. 
The study, conforming to the Declaration of Helsinki, was approved by our local ethic 
committee and patients signed an informed consent 
 
3.6 STATISTICAL ANALYSIS 
 
All cases were coded and the measurements were made without knowledge of clinical data. 
Normality of distribution for quantitative variables was assessed by means of Shapiro-Wilcox 
statistics. Non normal variables were log-transformed. Group data were expressed as mean and 
SEM, or as median and IQR when appropriate. To compare means from two different groups we 
  50 
used the unpaired 2-tail Student’s t test or one-way analysis of variance (ANOVA) for normal 
data; for non-normal data Mann-Whitney’s U test or Kruskall-Wallis test were performed.  
Categorical data were analyzed by the chi-square test.  
Statistical analysis was performed using SAA statistical software version 9.1 (SAS institute, 
Carry, NC, USA). P values lower than 0.05 were considered statistically significant.  
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RESULTS 
 
4.1 POPULATION CHARACTERISTICS 
  
In the study period (January 2010 – December 2012) 74 patients were initially enrolled for the 
research, of which 66 have met the selection criteria, as in 8 cases a histological diagnosis of 
secondary malignancy was found. 
According clinical/functional inclusion criteria the three study groups included: 16 COPD 
patients, 32 smokers without COPD and 18 never smokers. 
The most important clinical data of the three groups are listed in table 4.1. 
 
  
COPD 
(16) 
Smokers 
(32) 
Never Smokers 
(18) 
p 
Age (years) 72 ± 7 68 ± 9.6 64 ± 12 NS 
Sex (M/F) 13/3 25/7 6/12 #@ 0.002 
BMI (Kg/m2) 27 ± 4 27 ± 4 27 ± 4 NS 
Smoke Pack-year  46 (IQR 33-55) 35 (IQR 15-48) 0 <0.001 
FEV1 (% of predict) 71 ± 14 # 93 ± 19 114 ± 19 <0.001 
FEV1/VC (%) 58 ± 9 *# 75 ± 7 81 ± 6 <0.001 
FEV1/FVC (%) 62 ± 10*# 81 ± 6 85 ± 8 <0.001 
FVC (% of predict) 91 ± 18 90 ± 17 111 ± 17 #@  <0.001 
RV (% of predict) 122 ± 18 *# 106 ± 18 106 ± 19 0.015 
RV/TLC (%) 113 ± 17 109 ± 16 102 ± 15 NS 
PaO2 (mmHg) 72 ± 7 75 ± 7 74 ± 7  NS 
PaCO2 (mmHg) 39 ± 3 38 ± 3 37 ± 3 NS 
WBC (x 10.9/L) 8.1 ± 3.2 7. 7 ± 2.3 7.5 ± 2 NS 
RBC (x 10.12/L) 4.8 ± 0.5 4.5 ± 0.6 4.6 ± 0.7 NS 
Basophil cell (x 10.9/L)  0.04 (IQR 0.03-
0.06 
0.02 (IQR 0.02-
0.04) 
0.02 (IQR 0.02-0.03) 0.002 
ESR (mm/h) 28 ± 14 33 ± 20 38 ± 27 NS 
CRP (mg/L) 5.9 (IQR 3-10.1) 3.5 (IQR 2.9-17.8) 3 (IQR 2.9-14.7) NS 
Adenocarcinoma 
histology (%) 
73  61  56  NS 
 
* COPD vs Smokers p < 0.05,  
# COPD vs Never smokers p < 0.05,  
@ Smokers vs Never smokers p < 0.05 
 
Table 4.1. Main demographic, clinical and functional patients characteristics. Data are expressed as 
mean and SEM, except Smoking pack-year, Basophil cell amount and CRP reported as median and 
IQR.  
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The three study groups presented homogeneous demographic characteristics (age, height, weight, 
BMI) except for sex, with a significant greater proportion of women in the never-smoker group. 
Regarding smoking history, COPD and smoker patients were comparable. 
Concerning PFTs, as expected, COPD group evidenced a statistically reduction in most of the 
respiratory functional parameters (FEV1%, FEV1/VC, FEV1/FVC, PEF%, TLC%, RV%, 
FRC%) even if the Motley index (RV/TLC), sign of pulmonary hyperinflation from emphysema, 
did not differ in the three populations. Conversely, FVC% was higher (111±17%) in never 
smoker patients compared to smokers without COPD (90±17%, p<0.001) and COPD patients (91 
± 18%, p= 0.003). According to GOLD staging for COPD patients, we reported 3 stage I and 7 
stage II. Blood tests analyses did not show significant changes even for systemic inflammatory 
markers; the only altered value is an increase in percentage of basophil cells in COPD patients 
compared to smokers. The choice to include in the study only patients with peripheral lung 
cancer has undoubtedly led to a selection bias, affecting the predominant histologic profile. 
Indeed, in all the three populations there is a clear predominance of the glandular form, with 
percentages ranging from 63% in the COPD group, to 71 % in the smokers and 56% in never-
smokers (p = ns). In order to obtain results not affected by different histotypes, we decided to 
analyze tumor functional, molecular and morphological assessment only in the prevalent 
histology, adenocarcinoma. Therefore, the study population was composed of 43 patients, of 
which 10 COPD patients, 23 smokers without COPD and 10 non-smokers. As shown in Table 
4.2, the main demographic and functional parameters reflected those of the previous population, 
not showing significant differences among the 3 groups except for the male/female ratio, which 
result reversed in never smokers and for lung function, reduced in COPD patients. Even in this 
case, FVC% was higher (115±11%) in never smoker patients compared to smokers (93±17%, 
p=0.001) and COPD (91 ± 19%, p= 0.003). 
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COPD 
(10) 
Smokers 
(23) 
Never smokers 
(10) 
P 
Age (years) 71 ± 7 68 ± 7 68 ± 9 NS 
Sex (M/F) 8/2 19/5 3/7 *
@
 
0.02 
BMI (Kg/m2) 27 ± 4 27 ± 4 28 ± 4 NS 
Smoke Pack-year  47 ± 29 39 ± 32 0 0.001 
FEV1 (% of predict) 71 ± 15 *
#
 
95 ± 19 119 ± 13 <0.001 
FEV1/VC (%) 58 ± 8 *
#
 
74 ± 8 80 ± 3 <0.001 
FEV1/FVC (%) 60 ± 10 80 ± 7 87 ± 10 <0.001 
FVC (% of predict) 91 ± 19 93 ± 17 115 ± 11*
@
 
0.003 
RV (% of predict) 123 ± 17 *
#
 
107 ± 19 102 ± 20 0.059 
RV/TLC (%) 114 ± 19 108 ± 18 98 ± 14 NS 
PaO2 (mmHg) 75 ± 6 76 ± 7 74 ± 7  NS 
PaCO2 (mmHg) 40 ± 3 39 ± 2 37 ± 3 NS 
WBC (x 10.9/L) 7.3 ± 2.5 7. 7 ± 2.7 7.8 ± 2.6 NS 
RBC (x 10.12/L) 4.7 ± 0.5 4.5 ± 0.6 4.6 ± 0.6 NS 
Basophil cell (x 
10.9/L) 0.03 (IQR .03-0.06) 
#
 
0.02 (IQR 0.02-
0.03) 
0.02 (IQR 0.02-0.03) 0.048 
ESR (mm/h) 27.6 ± 14 32.9 ± 21 33 ± 34 NS 
CRP (mg/L) 6.4 (IQR 4.1-9.9) 3.4 (IQR 2.9-
6.3) 
3 (IQR 2.9-3.4) NS 
SUV max  5.83 ± 3.91 9.46 ± 5.77 7.31 ± 4.96 NS 
 
* COPD vs Smokers p < 0.05,  
# COPD vs Never smokers p < 0.05,  
@ Smokers vs Never smokers p < 0.05 
 
Table 4.2. Main demographic, clinical and functional patients characteristics in patients with 
adenocarcinoma histology. Data are expressed as mean and SEM, except Basophil cell amount and 
CRP reported as median and IQR.  
 
 
The analysis of tumor functional assessment through 18FDG PET-CT scan did not evidence 
significant differences in the three populations with values of mean SUVmax in COPD patients, 
smokers and never smokers group of 5.83 ± 3.91, 9.46 ± 5.77 and 7.31 ± 4.96, respectively. 
Although not statistical significant, a strong trend of increase in the SUV max in smoker-related 
tumours compared to COPD-related cancers (9.46 ± 5.77 vs 5.83 ± 3.91, p=0.08) was observed. 
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4.2 HISTOLOGIC EVALUATION 
 
According to WHO guidelines, a diagnosis of adenocarcinoma histology was found in all 
patients. In one case of never smokers group an additional well-differentiated stage I 
neuroendocrine tumor was observed in tissue specimen.   
The maximal lung tumour diameter was measured and the mean values for each group was 
3.11±1.3 cm (COPD patients), 3.2±0.1 cm (smokers) and 3.1±1.1 cm (never smokers), without 
statistical difference.  
Pathological staging of all patients was reported in table 4.3 and revealed a comparable 
stratification between the groups with a majority of early stages (p=n.s.). 
Stage IIIA was due to mediastinal nodal involvement not evidenced at pre-operative 
investigation, except in one never smoker patient that was staged T4 for an ipsilateral lung 
nodule. The smoker patient without COPD with stage IV underwent to left upper lobectomy for 
two lung metastasis of a previous resected adenocarcinoma.        
 
  
 
COPD Smokers Never smokers 
Stage IA 4 (40%) 5 (22%) 4 (40%) 
Stage IB 3 (30%) 10 (43%) 1 (10%) 
Stage IIA 1 (10%) 2 (9%) 3 (30%) 
Stage IIB 1 (10%) 2 (9%) 0 
Stage IIIA 1 (10%) 3 (13%) 2 (20%) 
Stage IIIB 0 0 0 
Stage IV 0 1 (4%) 0 
 
Table 4.3. Stage distribution in study population without significant differences in distribution.     
 
 
The evaluation of the histological analysis was reported in Table 4.4. 
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 COPD Smokers Never Smokers P 
Lepidic pattern (%) 25 (IQR 10-30) 0 (IQR 0-10) 25 (IQR 0-30) 0.01 
Mucinous Lepidic Pattern 
(%) 
0±0  4±14  0±0 NS 
Acinary pattern (%) 44±22 44±32 49±26 NS 
Papillary pattern (%) 0 (IQR 0-0) 0 (IQR 0-13) 15 (IQR 10-20) NS 
Solid pattern (%) 10 (IQR 0-20) 20 (IQR 6-70) 0 (IQR 0-0) 0.045 
Ki67/MIB1 (%) 30±30 50±25 24±18 0.013 
Necrotic remodelling 18±23 20±23 2±4 NS 
Inflammatory remodeling 28±22 30±22 33±20 NS 
Fibrotic remodelling 24±20 28±22 28±18 NS 
 
Tab 4.4. Main histological results in three study populations. Data are expressed as mean and SEM, 
except lepidic, papillary and solid pattern reported as median and IQR.  
  
We can observed a significant increase of the lepidic pattern (Fig. 4.1) percentage in COPD 
patients and never smokers  tumours compared to smokers (25% (IQR 10-30%) vs 25% (IQR 0-
30%) vs 0% (IQR 0-10%), respectively, p=0.01).  
The mucinous lepidic variant was found only in smokers but no differences were observed with 
the other groups (0±0% vs 4±14 vs 0±0, respectively, p=NS).  
 
 
Fig. 4.1. Lepidic pattern of invasive adenocarcinoma: tumor cells, type II pneumocytes and Clara 
cells, grow along the surface alveolar walls. 
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At the same time, an increase of the solid component (Fig. 4.2) in smokers compared with other 
groups (20% (IQR 6-70%) vs 10% (IQR 0-20%) in COPD patients vs 0% (IQR 0-0%) in never 
smokers, p=0.045) was present.  
 
 
Fig. 4.2.Solid pattern of invasive adenocarcinoma: sheets of tumor cells with abundant cytoplasm 
and mostly vesicular nuclei with  several conspicuous nucleoli. 
 
No differences were observed for the intermediate histological components, the acinar (44±22%, 
44±32%, 49±26% for COPD patients, smokers and never smokers, respectively) and papillary 
pattern, including also micropapillary variant (0% (IQR 0-0%), 0% (IQR 0-13%) and 15% (IQR 
10-20%) for COPD patients, smokers and never smokers, respectively) (Fig. 4.3).    
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Fig. 4.3. Different lepidic, mucinous lepidic, acinar, papillary and solid pattern distribution in the three 
study groups. 
 
 
Quantification of Ki67/MIB1 (Fig. 4.4) showed an higher replication tendency in smoker cases 
without COPD compared to COPD patients and never smokers (50±25% vs 30±30% vs 
24±18%, respectively, p=0.013) and was reported in Fig. 4.5. 
 
Fig. 4.4. Ki67/MIB1 expression in a smoker (A) and in COPD case (B). 
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Fig. 4.5. Cell replication assessment by Ki67/MIB1 evaluation showed significan increase in smoker 
group compared to COPD patients and never smokers.   
 
 
Finally, quantification of peri and intratumoral remodeling (Fig. 4.6) brought to an increase in 
the necrotic component in the group of smokers (20±23%) and COPD (18±23%), compared to 
never-smoker cases (2±4%, p= 0.03 and p=0.05, respectively). By contrary, there were no 
differences concerning the assessment of inflammation (28±22%, 30±22% and 33±20%) and 
fibrotic remodeling (24±20%, 28±22% and 28±18). 
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Fig. 4.6. Intra and peri-tumoral remodeling in the three groups. 
 
 
4.3 GENETIC ANALYSES 
 
The mutation analysis of EGFR and K-RAS genes was performed in all adenocarcinomas. 
Concerning EGFR, no differences were found between the three groups, although a trend of 
increased presence of this genetic alteration was observed in non-smokers patients (40%), 
compared to COPD patients (10%) and smokers (10%). 
Analysing KRAS, as expected, we report a trend of increased mutation in smokers compared 
than never smokers (47% vs 10%, p=0.09). At the same time, a trend of difference was present 
even comparing the group of smokers to that of COPD, who had a smoking similar history (47% 
vs 30%, p=NS). Assuming that this trend could be evidenced, increasing the number of cases, we 
included in this analysis a retrospective series of 135 patients with a previous KRAS genetic 
evaluation, which PFTs and smoking history were reviewed in order to classify each case in the 
right group. We then looked at the new populations, reporting a significance higher percentage 
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of KRAS mutations in smoker patients without COPD compared to COPD patients and to never 
smokers (39% vs 15% vs 11%, p< 0.001, Fig. 4.4). 
 
 
Fig. 4.7. K-RAS mutation prevalence in a combined retrospective and prospective population. 
  
 Analyzing the whole population of 46 cases, we found that the presence of KRAS mutations 
was associated to an higher value of Ki67/MIB1 (60% (IQR 30-70%) vs 25% (IQR 10-45%), 
p=0.04) and higher solid pattern percentage (20% (IQR 20-75%) vs 5% (IQR 0-20%), p=0.02) 
compared to wild-type form. In addition a negative trend was observed between K-RAS 
mutation and lepidic pattern percentage (0% (IQR 0-30%) vs 15% (IQR 0-30%), p=0.125 in 
KRAS mutated and wild-type form, respectively, Fig. 4.5).     
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Fig. 4.8. Association of KRAs mutation with cell replication (Ki67/MIB1) and type of growth pattern 
(lepidic and solid). 
 
 
 
4.4 CHARACTERIZATION OF THE PERI-AND INTRA-TUMOR IL-17 CYTOKINE PATTERN 
 
Preliminary analysis of IL-17 expression performed in the groups of COPD patients and smokers 
without smokers showed a marked cytoplasmic infiltration both in lymohomonocyte and 
neoplastic cells. Although not significant a stronger  IL-17 expression was observed  in COPD 
cases compared to smokers without COPD (253 ± 50 vs 156 ± 109, p=NS, Fig. 4.9 and Fig. 
4.10). 
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Fig. 4.9. Histological view of IL-17 expression in COPD (A-B) and smoker  without COPD(C-D) 
related tumours.  A –B: both neoplastic cells  and lymphocyte are strongly marked. C-D: only a few of 
neoplastic and lymphocyte show mild-moderate immunostaining. 
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 Fig. 4.10.  IL-17 expression assessment in COPD and smokers group.  
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5. DISCUSSION 
 
Lung cancer is the most prevalent tumour worldwide and a common cause of cancer-related 
death [47]. Evidence now demonstrates that pathological subtype classification of “non small-
cell lung cancer” (NSCLC), a heterogeneous group of diseases, is central in selecting optimal 
treatment [110,111]. However, even if surgical and oncologic treatments have greatly improved 
in recent years overall based on better pathological and molecular diagnosis, lung cancer 
continues to present increasing frequency, poor long-term results and an unpredictable disease 
progression.  
The co-presence of other diseases in individual patients may strongly influence the 
carcinogenetic process, making it not only dependent on the classical risk factors. In this context, 
the relationship that exists between COPD and lung cancer is undoubtedly important. Several 
epidemiological studies have now firmly established the connection between the two diseases 
highlighting how COPD is by far the greatest risk factor for lung cancer amongst smokers [68]. 
Skillrud et al first assessed the risk of lung cancer in patient with COPD compared to a matched 
case-control study and estimated that the cumulative probability of developing lung cancer 
within 10 years was 8.8% for those with COPD and 2% for patients with normal function [112]. 
This indicates that ~1% of patients with COPD develop lung cancer each year, while only 0.2% 
of patients with normal function develop lung cancer (five-fold increased risk of lung cancer). 
Several cross-sectional studies, together with recently published prospective studies show 
smokers with COPD (or reduced FEV1) have up to 4-to 6-fold increased risk of lung cancer 
when compared with smokers with normal function. 
Furthermore 50-70% of patients diagnosed with lung cancer have spirometric evidence of COPD 
[113]. 
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While the main risk factor for the onset of both diseases is represented by cigarette smoke 
exposure, they also share a common genetic predisposition which justifies the incidence of these 
diseases in only a fraction of smokers [74]. 
This increased risk of lung cancer among smokers with COPD is probably due to activation of 
common signaling pathways for both diseases by tobacco smoke as well as by smoking-induced 
chronic inflammation which is a risk factor for both diseases. A causal relation between 
inflammation and cancer has already been proposed by Galen and later by Virchow [85], who 
observed inflammatory cell infiltration in malignant tissues and suggested that cancers arise at 
regions of chronic inflammation. The longer the inflammation persists, the higher the risk of 
associated carcinogenesis [114]. 
The importance of this inflammatory response has recently been highlighted, inviting a broader 
look at the possible involvement of the immune system in the pathogenetic events of COPD. 
Emerging evidences in this context have emphasized the role of adaptive immune responses, 
possibly with an autoimmune component due to the recognition of pulmonary self-antigens 
modified by cigarette smoking and to the failure of mechanisms regulating immunological 
tolerance [41]. Thus it is not surprising that COPD is associated with increased risk of 
developing lung cancer  due to the synergic effect of cigarette smoke and chronic inflammation. 
The histologic subtype more frequently associated with smoker COPD is squamous cell 
carcinoma however no other specific clinical, morphological and/or molecular details have been 
described in lung cancer associated with COPD. 
In our research study we speculated that lung cancer developed in COPD patients has a different 
clinical/morphological/molecular phenotype compared to lung cancer of smokers without COPD  
and never smoker subjects.  The comparison was mainly performed within the category of 
smoking patients: COPD versus smokers without COPD, with  the main objective to assess the 
impact of COPD on the tumor phenotype. Never smokers were an important control group in our 
research study even if it should be noted that tumours arising in thi category of patients have 
peculiar genetic substrates and mechanisms. The findings of EGFR mutation balanced by the 
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low KRAS–mutation frequency in never-smoking cases enrolled in the project is proof of these 
characteristics. 
The decision to perform the analysis only in adenocarcinomas was surely influenced by the high 
percentage of this histologic type determined by the selection bias of inclusion/exclusion criteria 
and by the need to obtain results not affected by different histotypes. However, this choice 
reflects the epidemiology trend of lung cancer with adenocarcinoma incidence that has now 
surpassed that of squamous cell carcinomas in both sexes, possibly due to changes in cigarette 
smoke composition and/or inhalation [115].  
A fundamental point of our prospective study is represented by the fact that the study population 
included COPD and well matched smoker patients without COPD both for age, sex and smoking 
history, well known factors which may influence lung carcinogenesis. Among PFTs, excluding 
those specific for COPD (FEV1%, FEV1/VC, FEV1/FVC, PEF%, TLC%, RV%, FRC%), an  
approximately equal decrease of FVC percentage in patients with a smoking history (smokers or 
COPD) was observed. Functional impairment in these patients may be the spirometric expression 
of parenchymal damage caused by smoke exposure. With regard to biohumoral, and in particular 
to inflammatory indices, except for basophils, we did not observe significant difference between 
COPD and smoker patients. The raised number of blood basophils in COPD patients could 
reflect an anti-tumour immune response to circulating antigen. There are only few papers that 
focus on the significance of an increased number of basophils and  cancer and even fewer for 
lung cancer.   Basophils mediators are reported to attract eosinophils in the site of nematode 
infestation and arm them for more potent killing of the nematodes [116]. It is possible that the 
link between the numbers of circulating basophils and eosinophils in lung cancer patients lies in 
a similar interaction in relation to the tumour, since eosinophil infiltration of the tumours was 
associated with both blood eosinophilia and better prognosis [117].  
Tumour functional assessment was evaluated through 18FDG PET-scan which has been imposed 
as a strategic diagnostic and staging tool for lung cancer. 18FDG PET-scan has recently been 
proposed as a prognostic examination in particular through the SUV index since it seems closely 
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related to tumour biological aggressiveness [118]. An important meta-analysis performed by 
Berghmans et al [67] in 2008 took into consideration 13 studies including 1474 patients with 
different stages of NSCLC. They reported that in 11 studies a high SUV was identified as a poor 
prognostic factor for survival although two studies found no significant correlation; in addition 
they estimated an overall combined hazard risk (HR) for the 13 reports of 2.27. Nair et al. 
recently published a clinical study where they analyzed the biologic basis for the use of FDG as a 
biomarker, founding that four of eight single genes associated with FDG uptake (LY6E, 
RNF149, MCM6, and FAP) were also associated with survival [119]. A lower SUV was detected 
in our COPD lung cancer. This is likely due to a less proliferative index of this neoplasia 
compared to lung cancer of smokers without COPD.  Different works in the literature have 
reported a significant relation between tumour proliferation detected by MIB1/Ki67 and SUV, 
highlightening  the significant value of FDG as an additional prognostic instrument [120]. The 
histological analysis of neoplastic patterns associated in our study groups revealed interesting 
data, emphasising significant differences. 
From a morphological point of view adenocarcinoma of COPD patients showed less frequent 
solid and more frequent lepidic pattern and lower Ki67 proliferation. The more extensive 
necrosis present both in COPD patients and smokers with lung cancer seems to be the expression 
of direct smoking cellular damage. All these aspects would characterize this form as a less 
aggressive neoplastic phenotype. Regarding lepidic pattern, the mucinous variant was found only 
in the smokers and analysed separately for the other lepidic cases. Indeed the new classification 
of adenocarcinoma [49] has now divided the mucinous from the nonmucinous form, as multiple 
studies [121-123] indicated that tumours formerly classified as mucinous BAC have major 
clinical, radiologic, pathologic, and genetic differences from the tumours formerly classified as 
nonmucinous BAC. In particular, these tumours show a very strong correlation with KRAS 
mutation, whereas nonmucinous adenocarcinomas are more likely to show EGFR mutation and 
only occasionally KRAS mutation [124]. In addition, the neoplasms formerly termed mucinous 
BAC and now classified as invasive mucinous adenocarcinoma, has been recognized to have 
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invasive components in the majority of cases [125], leading to a different clinical prognosis 
compared to nonmucinous variants. 
Concerning the molecular data the finding of less frequent K-RAS mutation in lung COPD 
patients  was remarkable. This finding reinforces the concept that tumour related to COPD 
presented  different biological behaviour. The impact of KRAS alterations on prognosis has 
already been studied in lung cancer and two different meta-analyses suggested an association of 
KRAS with poorer survival [126-127].  
Our group in 2010 [128] also confirmed the impact of KRAS mutations on prognosis in a 
clinically selected group of advanced adenocarcinomas, highlighting the role of KRAS as an 
independent prognostic marker.  
The analysis of the pathway axis of IL 17 seems to be an important link between COPD and lung 
cancer providing a possible pathogenetic substrate for both diseases. In our study we observed 
the increased cytokine expression in lung cancer of COPD cases.  
A key role for this cytokine has already been emphasised in the context of autoimmune diseases 
[129], and more recently in COPD patients, where it seems to support the maintenance of 
chronic inflammation [99].  
New evidences of this axis in the neoplastic field  have been reported  remarking its crucial role 
also in lung [130]. The relationship between IL-17 and cancer, whether beneficial or 
antagonistic, continues to be a controversial issue. The majority of studies reported an important 
influence of this cytokine on the induction of angiogenesis favoring vascular endothelial growth 
factor–VEGF-secretion and on neoplastic cell growth. [107] through the alteration of 
immunosurveillance component [108].  
There are still no evidence in the literature that describe the presence and the role of this cytokine 
in adenocarcinoma associated to COPD. In our study, the small number of subjects certainly 
influenced the observed results and probably the lack of a significant difference. However, what 
seems to emerge is that the IL-17 pathway, recently demonstrated to be involved in the complex 
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immunological background of COPD, could play a key role in cancer development/progression 
of  patients with COPD compared to smokers without COPD. 
In conclusion the scenario that emerged from our research study is the presence in COPD 
patients of a different cancer to that of matched case smokers without COPD. Clinical, 
biohumoral, morphological and molecular findings of COPD lung cancer showed stigmata of 
lower aggressiveness and invasiveness lung cancer phenotype.  
It might be speculated that alternative mechanisms of carcinogenesis are involved in the 
development/progression of COPD related lung cancer. Given the importance of inflammation in 
the pathogenesis of COPD the involvement of other pathways, such as IL-17, mainly driving 
inflammatory mediated carcinogenesis could be suspected. 
The main limitation of our research is represented by the low number of patients especially in the 
COPD group. Moreover the absence of COPD advanced stages does not allow assessment of the 
presence of any differences in inflammatory and neoplastic phenotype within the GOLD staging. 
Finally, the short follow-up of these patients, considering also the early disease stages included 
in the study, does not allow us to perform any survival analysis. 
 
Future research  
The availability of large amount of materials properly stored in a dedicated tissue archive will be 
able to expand the knowledge of neoplastic phenotypes associated with study populations.  
In this field, the characterization of mmunophenotype inflammatory cell infiltration both in 
peritumoral inflammatory infiltrate and in distant areas with particular attention to lymphocytic, 
macrophagic and cytokine patterns will be of great importance.  
The presence of liquid samples as blood and BAL will also lead to the research for possible 
peripheral biomarkers of disease that can provide predictive and prognostic information related 
to the neoplastic process. Finally, the analysis of medium-term results of survival and local or 
distant recurrence could support the preliminary data obtained in this study proposing a different 
lung cancer phenotype in COPD patients which show sign of less aggressiveness.  
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New knowledge of mechanisms at the basis of COPD lung cancer would be of considerable help 
in the fight against lung cancer both for individualized follow-up and for therapeutic 
perspectives, providing a rationale basis to develop targeted and more effective treatments to 
prevent or, at least, slow down cancer evolution (anti-inflammatory immunomodulatory or 
biological therapies).  
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